Interpace Biosciences, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
IDXG Over the counter 3840 www.interpace.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Interpace Biosciences, Inc.

Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results - Mar 30th, 2026 2:01 pm
Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure - Jan 20th, 2026 7:00 am
Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners - Dec 3rd, 2025 10:12 am
Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results - Nov 12th, 2025 2:01 pm
Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting - Sep 15th, 2025 7:15 am
Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results - Aug 7th, 2025 2:05 pm
Interpace Biosciences Announces First Quarter 2025 Financial and Business Results - May 8th, 2025 2:05 pm
Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk - Apr 24th, 2025 2:00 pm